Portal Access, a tumor-focused medical device startup, has closed its $7 million Series A finance round.
The company said more than 80% of the round was led by US physician investors, including oncologists, interventional radiologists, cardiologists and vascular surgeons.
Additional investors include partnerships from an unknown US-based venture capital fund.
What it does
The company manufactures Flexi-Port SLF-TANL is a subcutaneous port developed to streamline vascular access in tumor patients.
The company uses funds to support filing 510(k) to the FDA The company says the Flexi-Port SLF-TANL is expected to be expected in July 2025, and is scheduled to launch in the US market in 2026.
In a statement, the portal said Flexi-Port SLF-TANL devices help minimize treatment delays, procedural risks, and total healthcare costs.
“Closing this funding round represents an important milestone as we work towards regulatory approval.” Michael Tal, founder and CEO of Portal Access, said in a statement.
“Flexi-Port SLF-TANL is designed with a focus on simplicity, stability and scalability, and may support more efficient workflows in oncological access settings. This is a solution for both clinicians and patients, and was created with the most optimal patient outcomes and experience in mind. ”
Market Snapshot
Other companies in the field of oncology include Atropos Health announced its strategic partnership in April with Ontada, a McKesson business involved in community oncology. Ontada is connected to the American Oncology Network, which provides real-time data, insights, and research into ways to treat it in the community.
In April, The concert announced a multi-year agreement with Pharmaceutical and Biotechnology’s leading Bayer, using Concertai’s Translational360 and AI SaaS offerings.
This product uses AI and machine learning insights to promote the clinical development of precision oncology.
The agreement aims to use Concertai’s Translational360 Offering, an integrated research-level longitudinal clinical molecular database that leverages the CancerlinQ network of cancer patient data anonymized from more than 9 million records across all 50 states.
March, Flatiron Health has deployed the Flatiron Clinical Pipe for Multicenter NRG Clinical Trials in collaboration with NRG Oncology, a clinical research consortium within the National Cancer Institute’s National Clinical Trial Network, which has more than 1,300 research sites around the world.
Flatiron Clinical Pipe is an electronic data capture (EDC) connector to electronic health records (EHR) that aims to improve efficiency and reduce the time and effort required to enter clinical research data.
This collaboration aims to broaden use cases for the Flatiron clinical pipe to include NCTN-sponsored research by applying Flatiron’s EHR-EDC technology to reduce the burden on NRG clinical trial site teams, facilitate data management, and speed up research timelines.
